Engineering the skin microbiome

Azitra demonstrates feasibility of engineering the skin microbiome to treat serious skin conditions

Register for free to listen to this article
Listen with Speechify
FARMINGTON, Conn.—Researchers from Azitra, Inc., in collaboration with The Jackson Laboratory (JAX), have demonstrated the feasibility of engineering a commensal bacterium to deliver a key therapeutic protein to the skin. Azitra will be presenting results from the joint research showing the successful genetic engineering of Staphylococcus epidermidis to produce high levels of functional LEKTI protein, a protease inhibitor involved in regulating the rate of skin loss.
The new research will be presented on April 10 by Travis Whitfill, MPH, founder and chief scientific officer of Azitra. The oral presentation, entitled “Engineering the Microbiome to Treat Netherton Syndrome, a Rare Skin Disease,” will be held at the Keystone Symposia on Skin Health and Disease, from April 8-11, 2019 in Hanover, Germany.
The company has designated the engineered LEKTI-expressing S. epidermidis strain as AZT-02. The research team, including Julia Oh, Ph.D., a skin microbiome expert at JAX, has also shown that engineered S. epidermidis efficiently colonizes skin in both wild type mice and in a mouse model of broken skin. Applied topically, AZT-02 offers the prospect of continuous and cost-effective delivery of functional LEKTI to the skin offering the potential to treat the severe genetic skin disease Netherton syndrome (NS).
S. epidermidis is a normal constituent of the skin microbiome, and has been shown to help maintain healthy skin by improving the water and lipid content of the skin, decreasing inflammation, promoting tissue repair and suppressing the levels of undesirable bacteria — including Staphylococcus aureus. Azitra’s core technology combines these characteristics of S. epidermidis with the added ability to deliver therapeutic proteins to the skin. This dual action aims to correct underlying skin defects and address the challenges of dysbiosis in order to treat complicated skin diseases.
“Azitra has developed a proprietary strain of S. epidermidis with an aim of using this bacterium as a platform for the treatment of skin diseases,” said Whitfill. “While this organism has the potential for use on its own to help maintain skin health, we are also developing it to serve as a unique delivery system for the cost-efficient production and topical delivery of important therapeutic proteins. These proteins are targeted to treat serious skin disorders. The work presented today clearly demonstrates the feasibility of this approach for the efficient, topical delivery of LEKTI to the skin. The strain, AZT-02, has the potential to be used as a treatment for Netherton syndrome, which is a rare genetic skin disease with no available treatment options.”
NS is a genetic disorder affecting 1 in 200,000 children which is caused by mutations in the SPINK5 gene responsible for making the LEKTI (lympho-epithelial Kazal-type related inhibitor) protein. LEKTI’s function is to inhibit protease enzymes in the skin that facilitate the shedding of skin cells. When LEKTI is absent (in severe cases) or has reduced activity (due to a more minor genetic defect), excess shedding occurs and the skin is sensitive, open, red and scaly. This is accompanied by a disruption of the skin’s barrier function, dehydration and potential exposure to allergens, infectious agents, toxic chemicals and other environmental hazards. Complications of NS are frequent, and newborns with the disorder are at risk of becoming dehydrated and developing skin infections or sepsis. There are currently few treatment options for NS.
“We have shown with this research that our proprietary strain of S. epidermidis can be engineered for the delivery of therapeutic proteins and can efficiently colonize both healthy and diseased skin,” Whitfill added. “Azitra is now planning further studies to evaluate the efficacy of AZT-02 for the potential treatment of NS. The company is also investigating other indications—such as atopic dermatitis—for additional therapeutic uses with this platform of delivering therapeutic proteins by a commensal skin organism.”

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue